Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202270 | 0.79 | HTR2A (0.40) | RPS6KA5HTR2AHTR2C | |
| SCHEMBL29571670 | 0.78 | HTR2A (0.39) | RPS6KA5HTR2AHTR2C | |
| SCHEMBL18202323 | 0.78 | HTR2A (0.39) | RPS6KA5HTR2AHTR2C | |
| SCHEMBL18202194 | 0.76 | EGFR (0.42) | RPS6KA5HTR2AHTR2CDYRK1A | |
| SCHEMBL18239591 | 0.75 | JAK3 (0.37) | RPS6KA5JAK3 | |
| SCHEMBL18202201 | 0.74 | CSNK1D (0.32) | RPS6KA5HTR2AHTR2C | |
| SCHEMBL18229907 | 0.74 | PTGDR2 (0.37) | JAK3HTR2AHTR2C | |
| SCHEMBL18202203 | 0.72 | PABPC1 (0.37) | HTR2AHTR2C | |
| SCHEMBL18229866 | 0.71 | PTGDR2 (0.34) | HTR2AHTR2C | |
| SCHEMBL17822333 | 0.69 | ALDH1A1 (0.39) | RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | RPS6KA5 188/4885JAK3 331/4885HTR2A 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.